Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine for MDD in advanced cancer
NCT04471818Phase 2Completed
- Start
- Sep 2019
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ketamine in major depressive disorder (MDD). Started Sep 2019; status: completed.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04471818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04471818.